Patients with Hodgkin Lymphoma
We Need Your Help!
Lymphoma Canada is preparing a submission for the Canadian Drug Agency (CDA) on an upcoming drug review on Nivolumab for patients with previously untreated stage III or IV classical Hodgkin lymphoma.
Nivolumab (also known as Opdivo) is a PD-1 immune checkpoint inhibitor that works by reactivating T cells to target tumor cells. Nivolumab is being submitted for use in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of patients with previously untreated stage III or IV classical Hodgkin lymphoma.
If you have Hodgkin Lymphoma (HL) and have received this treatment, you can help by completing our survey! You can still participate in this survey if you have not received this therapy.
The survey provides us with patient input required for the submission. CDA uses this information to help make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Wednesday, January 15, 2025, and should only take between 15-20 minutes of your time.
Please share and help us spread the word.
Thank you for your support.
Follow us on Social Media to stay up to date and informed on all things Lymphoma Canada!
